Trials / Recruiting
RecruitingNCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 204 (estimated)
- Sponsor
- Evopoint Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .
Conditions
- Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Prostate Cancer
- Small-cell Lung Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Other Solid Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XNW5004 | XNW5004 an EZH2 inhibitor, BID, administered in continuous |
| DRUG | KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection | KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks. |
Timeline
- Start date
- 2023-09-20
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
- First posted
- 2023-09-05
- Last updated
- 2024-02-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06022757. Inclusion in this directory is not an endorsement.